Endometriosis - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 117 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Endometriosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Endometriosis - Pipeline Review, H2 2014', provides an overview of the Endometriosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Endometriosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Endometriosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Endometriosis Overview 10
Therapeutics Development 11
Pipeline Products for Endometriosis - Overview 11
Pipeline Products for Endometriosis - Comparative Analysis 12
Endometriosis - Therapeutics under Development by Companies 13
Endometriosis - Therapeutics under Investigation by Universities/Institutes 16
Endometriosis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Endometriosis - Products under Development by Companies 21
Endometriosis - Products under Investigation by Universities/Institutes 22
Endometriosis - Companies Involved in Therapeutics Development 23
Euroscreen S.A. 23
Takeda Pharmaceutical Company Limited 24
Neurocrine Biosciences, Inc. 25
Astellas Pharma Inc. 26
Kissei Pharmaceutical Co., Ltd. 27
SK Chemicals Co., Ltd. 28
Bayer AG 29
Addex Therapeutics Ltd 30
Evotec AG 31
ValiRx Plc 32
Repros Therapeutics Inc. 33
Dongkook Pharmaceutical Co., Ltd. 34
Lipicard Technologies Limited 35
Orphagen Pharmaceuticals, Inc. 36
Peptron, Inc. 37
PregLem SA 38
EndoCeutics, Inc. 39
Isifer AB 40
ElexoPharm GmbH 41
APAvadis Biotechnologies Srl 42
AbbVie Inc. 43
Forendo Pharma Oy 44
Endometriosis - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Target 47
Assessment by Mechanism of Action 50
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
elagolix sodium - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
leuprolide acetate SR - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
(acolbifene hydrochloride + GnRH agonist + prasterone) - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
relugolix - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
telapristone acetate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PGL-2001 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
KLH-2109 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ASP-1707 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Endole - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
bentamapimod - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ESN-364 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
BAY-1026153 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NCE-403 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ADX-68692 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SR-16234 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
VAL-201 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Drugs for Endometriosis - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Peptides for Cancer and Endometriosis - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
EVE-104 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
triptorelin pamoate biosimilar - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
goserelin biosimilar - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
LT-6121 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Synthetic Peptide to Target GPR54 for Womens Health, Male Health and Oncology - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
VPE-001 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecules to Inhibit 17Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Drug to Target RERG for Endometriosis - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecules to Antagonize Steroidogenic Factor-1 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Small Molecules to Inhibit CD147 for Immunology, Oncology, Womens Health and Musculoskeletal Disorders - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecule To Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type 1 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Drug to Inhibit C-Jun for Endometriosis - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Drugs for Gynecological Disorders - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Endometriosis - Recent Pipeline Updates 98
Endometriosis - Dormant Projects 109
Endometriosis - Discontinued Products 110
Endometriosis - Product Development Milestones 111
Featured News & Press Releases 111
Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201 111
Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples 111
Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL201 111
Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis 112
Apr 25, 2013: ValiRx Receives Australian Patent For VAL201 113
Nov 13, 2012: Repros Presents Proellex Clinical Updates At Lazard Capital Markets 9th Annual Healthcare Conference 113
Oct 08, 2012: Repros Therapeutics's Proellex Receives FDA Acceptance For Reclassification Of Clinical Hold Status 113
Aug 27, 2012: FDA Provides Recommendations For Phase II Protocol For Repros' Proellex In Treatment Of Endometriosis 114
Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 115
Jul 16, 2012: FDA Provides Guidance To Repros For Conducting Phase II Study Of Proellex In Treatment Of Endometriosis 115
Appendix 116
Methodology 116
Coverage 116
Secondary Research 116
Primary Research 116
Expert Panel Validation 116
Contact Us 117
Disclaimer 117

List of Tables
Number of Products under Development for Endometriosis, H2 2014 11
Number of Products under Development for Endometriosis - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Comparative Analysis by Unknown Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Investigation by Universities/Institutes, H2 2014 22
Endometriosis - Pipeline by Euroscreen S.A., H2 2014 23
Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 24
Endometriosis - Pipeline by Neurocrine Biosciences, Inc., H2 2014 25
Endometriosis - Pipeline by Astellas Pharma Inc., H2 2014 26
Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 27
Endometriosis - Pipeline by SK Chemicals Co., Ltd., H2 2014 28
Endometriosis - Pipeline by Bayer AG, H2 2014 29
Endometriosis - Pipeline by Addex Therapeutics Ltd, H2 2014 30
Endometriosis - Pipeline by Evotec AG, H2 2014 31
Endometriosis - Pipeline by ValiRx Plc, H2 2014 32
Endometriosis - Pipeline by Repros Therapeutics Inc., H2 2014 33
Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2014 34
Endometriosis - Pipeline by Lipicard Technologies Limited, H2 2014 35
Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2014 36
Endometriosis - Pipeline by Peptron, Inc., H2 2014 37
Endometriosis - Pipeline by PregLem SA, H2 2014 38
Endometriosis - Pipeline by EndoCeutics, Inc., H2 2014 39
Endometriosis - Pipeline by Isifer AB, H2 2014 40
Endometriosis - Pipeline by ElexoPharm GmbH, H2 2014 41
Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H2 2014 42
Endometriosis - Pipeline by AbbVie Inc., H2 2014 43
Endometriosis - Pipeline by Forendo Pharma Oy, H2 2014 44
Assessment by Monotherapy Products, H2 2014 45
Assessment by Combination Products, H2 2014 46
Number of Products by Stage and Target, H2 2014 49
Number of Products by Stage and Mechanism of Action, H2 2014 52
Number of Products by Stage and Route of Administration, H2 2014 54
Number of Products by Stage and Molecule Type, H2 2014 56
Endometriosis Therapeutics - Recent Pipeline Updates, H2 2014 98
Endometriosis - Dormant Projects, H2 2014 109
Endometriosis - Discontinued Products, H2 2014 110